{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" No specific durations were mentioned in the text.\n\n\"DURATION\": []", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" \"DURATION\": [\"after the fourth course\"]", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" \"DURATION\": []", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" \"DURATION\": []", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" \"DURATION\": []", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"DURATION\": [\"prolonged life expectancy\"]", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" \"DURATION\": []", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" \"DURATION\": []", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"DURATION\": []", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"DURATION\": [\"often involve initiating medications\"]\n\nIn this context, the duration of treatment is not explicitly stated, but it can be inferred that it is typically long-term for managing Parkinson's Disease.", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" \"DURATION\": []", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" \"DURATION\": []", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" No specific duration mentioned in the text.\n\n{\"DURATION\": []}", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" No duration information provided.", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" \"DURATION\": []", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"\"DURATION\"\": [\"\"]\n\nThis information does not provide any specific duration information. It only states that certain events occur when CB1Rs on presynaptic neurons are activated.", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" \"DURATION\": []", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"DURATION\": [\"subsequent reactions\"]}\n\nOr, if you want to include the duration of cannabis use:\n\n\"DURATION\": [\"reporting that one out of five patients experienced hallucinations after using cannabis\"]", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", ["\"DURATION\": []", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" {}", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" \"DURATION\": []", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"DURATION\": [\"in 2009-2010\"]", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" \"DURATION\": []\n\nThis information does not provide any duration information. It only mentions a range of prevalence in the South Korean population.", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" There is no specific duration mentioned in the text for this fact.\n\n\"Fact\": {}", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" \"DURATION\": []", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" \"DURATION\": []", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" \"DURATION\": []\n\nThis information does not provide any duration information. It only mentions the association between a specific SNP and the hypoglycemic effect of a drug.", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" No duration information provided.", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" There is no specific duration mentioned in the given text for the terms AUC, EMs, and PM. So, the \"DURATION\" field should be left empty for these terms.", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" \"DURATION\": []", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" There is no mention of a specific duration related to these local names for the shrub.\n\n\"DURATION\": []", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or processes. It is a general statement about the role and importance of cytochrome P450 (CYP450) enzymes in biotransformation.", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" {\"DURATION\": []}\n\nThis study focused on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on the activities of CYP1A2, CYP2C9, and CYP2C19.", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" \"DURATION\": []", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" \"DURATION\": []", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"DURATION\": [\"\"]\n\n(Note: No specific duration information was provided in the text.)", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" \"DURATION\": [\"chronically\"]", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of an event or process. The extraction was performed using water, but there is no mention of how long the extraction process took.", {}]], [38, "[44].", [" It is unclear from the provided text what duration is associated with the study or experiment described in reference [44]. Therefore, the \"DURATION\" field should be left empty for this reference.", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" \"DURATION\": []", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" \"DURATION\": []", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" \"DURATION\": []", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" \"\"DURATION\"\": [\"\"]\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions the identification of unique substrates for Oat1 and Oat3.", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" \"DURATION\": []", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" {}", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"DURATION\": [\"\"]\n\n(Note: No specific duration information was provided in the given text.)", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" \"DURATION\": [\"96 hours\"]", {}]], [47, "Elliot et al.", [" \"DURATION\": []\n\nThis information does not provide any duration information. It is just a citation.", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"DURATION\": []", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" \"DURATION\": []", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" \"DURATION\": [\"from the day before until 2 days after taking gliclazide\"]", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" This is not a duration, it is a year and represents the publication date of a study.", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"DURATION\": []\n\nThe text does not provide information about the duration of events or studies related to the cited references.", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" I'm unable to extract any information related to durations from the given text \"Park et al.\" as it only refers to the authors of a study.", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" No information for \"DURATION\" field.", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" {}\n\n\"DURATION\": []\n\n\"ANA\": [\"1 : 40\"],\n\"smooth muscle antibody\": [\"1 : 80\"]\n}\n\nNote: ANA and smooth muscle antibody are not durations, but entities. They are included for completeness.", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" \"\"DURATION\": []\"\"\"\n\nThis text does not provide any information about the duration of events or processes. It only describes the current state of the liver histology.", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" I cannot directly parse the information from this sentence as it does not provide specific durations. However, I can assume that Tables 1, 2, and 3 likely contain information about various features of Case 1, but the durations associated with these features are not mentioned in the given text.", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" No specific durations mentioned in the text.\n\n{\"DURATION\": []}", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"DURATION\": [\"\"]\n\n(Note: No specific duration information was provided in the text regarding the use of black cohosh for menopause symptoms.)", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" \"DURATION\": [\"despite discontinuation\"]\n\nIn this case, the liver failure occurred after the discontinuation of the herbal supplement. The duration of the herbal supplement use before the liver failure is indicated as \"despite discontinuation\".", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or processes. It describes a general mechanism that occurs when a drug or metabolite binds to a host cellular protein and elicits an autoimmune response.", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" There is no specific duration mentioned in the text regarding the Naranjo Causality Scale.\n\n\"DURATION\": []", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"DURATION\": [\"\"]\n\n(No specific duration information was provided in the text.)", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" {}\n\n\"DURATION\": []\n\n(This information does not provide any specific duration information.)", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" No duration information provided.", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" \"DURATION\": []", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" \"DURATION\": []", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" \"\"DURATION\": []\"\"\"\n\nThis line does not provide information about the duration of an event or treatment. It is simply stating the dosage administered to Group one and presenting the data in a specific format.", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" No specific durations were mentioned in the text.", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" \"DURATION\": []", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" No duration information provided.", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" \"\"DURATION\": []\"\"\"\n\nThis statement does not provide any information about the duration of events or processes.", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" There is no specific duration mentioned in this context.\n\n\"DURATION\": []", {}]], [74, "KY[2017]073).", [" This is likely a citation for a scientific article. It does not provide any information related to durations.", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" No specific duration mentioned in the text.", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" There is no specific duration mentioned in the text for the studies conducted by Nadia et al. (2012) and Fathilah et al. (2013). Therefore, the \"DURATION\" field should be left empty.", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" No duration information provided.", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" \"DURATION\": []\n\nThis passage does not provide any information about the duration of events or processes. It only mentions the volume and composition of the medium used for growing cells and conducting an assay.", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of events or processes. It is just reporting information about the two major classes of compounds isolated from the roots of KF, as reported earlier.", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of events or experiments. It only mentions that the inhibition of P-gp by the extract of L. pumila and its constituents was determined using calcein-AM and digoxin probes, and refers to a previous study by Rautio et al. (2006).", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" This information does not provide any duration of events. It is just a statistical analysis method and significance level indicators. No need to include in the output.", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"DURATION\": []", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" \"DURATION\": [\"of specific relevance\"]\n\n\"DURATION\": [\"increase in the prevalence\"]\n\n\"DURATION\": [\"\"]\n\n(Note: The text does not provide specific durations for the anti-diabetic, anti-obesity, and cardio-protective effects of rooibos extracts being of relevance or the increase in the prevalence of diabetes and obesity.)", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that flavonoids are responsible for the modulation of certain enzymes.", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of an event or process. It only mentions a qualitative screening method used to identify potential inhibitory effects on certain enzymes (CYP2C8, CYP2C9, and CYP3A4).", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" \"\"\n\n\"DURATION\": []\n\n[The text does not provide any information about durations of events related to the mentioned enzymes and organic solvents.]", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"DURATION\": [\"over 30 min\"]", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"DURATION\": [\"\"]\n\nThe text does not provide information about durations of specific events related to CYP3A4 activity or IC CYP2C9.", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of an event or process. It only describes the preparation of stock solutions using distilled water.", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" There is no information about durations in this text.\n\nEntities: quercetin, sulfaphenazole, ketoconazole, positive CYP2C8 inhibitor, positive CYP2C9 inhibitor, positive CYP3A4 inhibitor.", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" \"DURATION\": [\"This in vitro study\"]", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" No duration information provided.", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" No duration information provided.", {"Herb name": ["Echinacea"]}]], [94, "2).", [" I'm assuming you're asking for the duration mentioned in the second sentence of the text.\n\n\"Animal model experiments, surveys, and small pilot studies show potential benefits in IBD treatment over short periods (8 weeks), while longer use (6 months) is associated with a higher rate of surgery (reviewed in [123]).\"\n\n\"DURATION\": [\"8 weeks\", \"6 months\"]", {}]], [95, "This result was statistically not significant.", [" {}", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" No duration information provided.", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or treatments. It only mentions that caffeic acid derivatives and alkylamides are found in ethanolic liquid extracts for medicinal use.", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" \"DURATION\": [\"according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)\"]\n\nThis information does not provide any specific duration information. The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0) is a standardized method for reporting toxicities in clinical trials.", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" \"\"\n\n\"DURATION\": []\n\n\"This sentence does not provide any information about the duration of an event.\"", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" \"DURATION\": [\"from time zero to infinity\"]\n\n\"AUC0\u2013\u221e\": []\n\n\"t1/2\": []\n\n\"Cmax\": []", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" \"DURATION\": [\"in cycle 1 (before E. purpurea)\", \"in cycle 2 (after E. purpurea)\"]", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" \"\"DURATION\": [\"\"]\"\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that there is a figure (Figure 3) showing individual differences in docetaxel AUC0\u2013\u221e.", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" \"DURATION\": [\"using midazolam as a CYP3A4 probe\"]\n\nIn this case, the duration information is related to the studies being compared, not the experiment being described directly. However, it's important to include it for context.", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"DURATION\": []", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" \"DURATION\": []", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"DURATION\": []\n\n(This passage does not provide any information about durations of events.)", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" \"DURATION\": [\"using a gene reporter assay\"]\n\nThis information does not provide specific durations for events, only the method used to assess the induction potential of compounds on CYP3A4.", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" \"DURATION\": [\"\"]\n\n(Note: No specific durations were mentioned in this context.)", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"DURATION\": [\"in cancer patients\"]\n\n(Note: No specific duration mentioned for the studies on R101933, zosuquidar, but it can be assumed that they were likely administered during the time frame of the clinical trials.)", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" No information found for \"DURATION\" field.", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"\"DURATION\": []\"\"\"\n\nThis statement does not provide any information about the duration of events or processes. It is a general statement about the potential risk of CYP3A4-mediated interactions being product-dependent.", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" {\"DURATION\": [\"\"]}\n\n(No specific duration mentioned in the text)", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" \"DURATION\": [\"for 15 minutes\", \"for 20 minutes\"]}", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" \"DURATION\": []\n\nThis text does not provide any information about the duration of events or processes. It only mentions the monitored M/Z values of certain compounds under the positive electrospray mode of MS.", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" \"DURATION\": [\"for the calibration curve range\"]\n\nCalibration curve range was generated by:\n- 0.1\u201350 ng/mL for EC\n- 1\u2013500 ng/mL for EGCG, ECG, and EGC.", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"DURATION\": []", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"DURATION\": [\"for the identification of genotyping\"]\n\"DURATION\": [\"for 4 single-nucleotide polymorphisms (SNPs)\"]", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" \"DURATION\": []", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" \"DURATION\": []", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" \"DURATION\": [\"Day 1\", \"Day 15\"]}\n\nNote: The information provided in the text suggests that the concentration-time profiles and pharmacokinetics parameters were determined on Day 15, but the exact duration of the concomitant administration of digoxin and GTC is not explicitly stated. However, based on the context, it can be inferred that it was for a certain period of time, likely longer than a single day. Therefore, I assumed that the duration of concomitant administration was not explicitly mentioned for the sake of accuracy, but it can be inferred from the context.", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"DURATION\": [\"Day 1\"]\n\nThis study investigated the effect of GTC on the pharmacokinetics of digoxin.", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" No duration information provided.", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" \"DURATION\": [\"at the start of the study\"]", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" \"DURATION\": [\"in the RGE repeated administration group\", \"in the control group\"]\n\nThis suggests that the duration of methotrexate excretion being compared is during the administration of RGE in the former group and in the control group, without any explicit mention of a specific time frame.", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" \"DURATION\": [\"for 1 or 2 weeks\"]", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" No duration information provided.", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" {}\n\"DURATION\": []\n}\n\nNo specific duration information was provided in this statement.", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"\"DURATION\": []}\n\nThis passage does not provide any information about durations of events. It mentions the names of nuclear receptors (FXR and PXR) and their roles in regulating the expression of Bsep and P-gp.", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"DURATION\": [\"in animals and humans\"]\n\n(Note: No specific durations were mentioned in the provided references, but it can be assumed that the studies lasted long enough to prove the beneficial effects.)", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" No specific duration information was provided in this statement.", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" {}\n\n\"DURATION\": []\n\nThis conclusion statement does not provide any specific duration information.", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" No duration information provided.", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" No duration information provided.", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" \"DURATION\": [\"2 h after the last RGE treatment\"]", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" \"DURATION\": []", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"DURATION\": []", {}]], [137, "Contents of ginsenosides in RGE.", [" I cannot directly extract the durations from the given text as it does not provide information about the duration of an event related to the contents of ginsenosides in RGE.", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" \"DURATION\": []", {}]], [139, "2014; Dybro et\u00a0al.", [" \"DURATION\": []", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" \"DURATION\": []", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" No duration information provided.", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" \"DURATION\": [\"for 10 min\"]", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" No duration information provided.", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" \"DURATION\": [] # Half-life is not a duration of an event, it's a property of a substance.", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" No duration information provided.", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" \"DURATION\": []", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" \"DURATION\": []", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" \"\"DURATION\"\": []", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" No specific duration mentioned in the text.", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" \"\"DURATION\": []\"\"\"\n\nThis statement does not provide any specific duration information. It only indicates that further studies are required.", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" No specific duration information provided in this sentence.", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" \"DURATION\": []", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" I cannot directly parse the duration information from the given text as it does not provide any specific duration information related to the literature analysis. The text only mentions that there is a mechanism of interaction between TCM formulations and digoxin, which is described as \"A\" in the text. Therefore, there is no duration information to be extracted from this text.", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"DURATION\": [\"intravenously\", \"in vitro\"]\n\n\"Entities\": [\"digoxin\", \"citronellal\", \"Conioselinum anthriscoides\", \"Chuanxiong\", \"Vernonia amygdalina\", \"Biantaobanjiuju\", \"Tapinanthus sessilifolius\", \"Carica papaya\", \"Mugua\", \"Ginkgo biloba\", \"L.\"]", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" \"DURATION\": [\"\"]\n\n(Note: In this case, no specific duration information is provided in the text.)", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" I'm unable to extract any information related to durations from the given text, which only mentions the authors' names. Therefore, the \"DURATION\" field should be left empty for this entry.\n\n{\"DURATION\": []}", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"DURATION\": [\"in rats\", \"after the administration of C. pinnatifida Bunge (Shanzha) extract\"]\n\nThe study used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias. The results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract. This suggests that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias. This may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system.", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" \"DURATION\": []", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" \"DURATION\": []", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" No duration information provided.", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" \"\"\n\n\"DURATION\": []\n\nThis sentence does not provide any information about the duration of events or treatments.", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" \"DURATION\": []", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" {\"DURATION\": []}\n\nThis passage does not provide any specific durations of events. It is a general statement about the involvement of cytochrome P450 enzymes in human drug metabolism and their role in oxidative metabolism of xenobiotics and endogenous compounds.", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" \"\"DURATION\": []\"\"\"\n\nThis text does not provide any specific duration information related to the entities mentioned.", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" \"DURATION\": [\"in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials\"]", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"DURATION\": []", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"DURATION\": []\n\nThis section does not provide information about the duration of any events or treatments. It is a description of the plant material and the preparation of CAW-R61J.", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" \"DURATION\": [\"\"]\n\n(This text does not provide any information about the duration of events or processes.)", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"DURATION\": []", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" \"DURATION\": []", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" \"DURATION\": [\"30-minute\"]", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" {}", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" This text does not provide any information about durations.", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" I apologize for the confusion, but the text does not provide the information on the duration of the experiment for the logEC50 or logIC50 values mentioned in the previous response. Therefore, the \"DURATION\" field should remain empty for this entry.", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" No specific durations were mentioned in this text.\n\nTherefore, the \"DURATION\" field should be left empty.", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" This information does not provide any duration information. It is just the object name of a figure.", {}]], [177, "Mean\tS.D.", [" It is not clear in the context of the provided text if \"Mean S.D.\" refers to a duration of an event or a measurement of data. If it is a measurement of data, please provide the units of measurement for clarity. If it is a duration, please refer to the text for more context.", {}]], [178, "Mean\tS.D.", [" It is not clear in the context of the provided text if \"Mean S.D.\" refers to a duration of an event or a measurement of data. If it is a measurement of data, please provide the units of measurement for clarity. If it is a duration, please refer to the text for more context.", {}]], [179, "***P < 0.0001.", [" This is not a duration, it is a statistical significance measure. It indicates that the probability of observing the current result by chance is less than 0.0001, or 0.01%.", {}]], [180, "; data not shown).", [" {}", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" This citation does not provide any specific durations mentioned in the text. However, based on the context, it appears to be referencing studies that have been conducted over an unspecified period of time.\n\n\"Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).\"\n\nTherefore, no duration information can be extracted from this text.", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" \"DURATION\": []\n\nThis information does not provide any duration information. It only mentions IC50 values for different cytochrome P450 enzymes.", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or extract information from an external file. However, if the file contains information such as durations, please provide the information in the text of the article.", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" This information does not provide any duration information. It is just the name of a figure in the article.", {}]], [185, "Data shown are the means \u00b1 S.D.", [" {}\n\n\"DURATION\": []\n}\n\nThis information does not provide any specific duration information.", {}]], [186, "of triplicate determinations.", [" (No duration information provided)", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" \"DURATION\": []", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" No specific duration mentioned in the text.", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" \"DURATION\": [\"in humans\"]", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"\"DURATION\"\": []", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" {}\n\n\"DURATION\": []\n\nThis sentence does not provide any information about the duration of events or treatments. It only states that the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" \"\"DURATION\": []\"\"\"\n\nThis information does not provide any specific duration information related to the use of fimasartan in patients with hypertension and chronic kidney disease.", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" {\"DURATION\": []}", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" \"DURATION\": []", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" {\"DURATION\": []}", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" \"DURATION\": [\"for 24 hours\"]", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"DURATION\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" No duration information provided.", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" No duration information provided.", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {}\n\n\"DURATION\": []\n\n[Note: No specific duration information was provided in the text.]", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" \"DURATION\": [\"1 h\"]", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" \"DURATION\": [\"\"]\n\nExplanation: The text does not provide any specific duration information related to the entities mentioned. The text is discussing the accuracy of a bioanalytical method and the acceptance criteria for accuracy from regulatory agencies.", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" \"\"DURATION\": []\"\"\"\n\nThis passage does not provide any information about the duration of events or treatments. It only discusses the results of a study suggesting the use of fimasartan for hypertension treatment.", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" {\"DURATION\": []}\n\nThis passage does not provide any information about durations of events. It only mentions the use of previously published reports and the observation of different mass fragmentation patterns in the product ion mass spectra.", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" I assume you meant \"maximal power\" (M.P.) in the context of muscle strength. Here's the updated information:\n\n\"DURATION\": [\"for 12 weeks\"]\n\nMuscle strength (mean 7.7% for QMS) and maximal power (M.P.) were improved.", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" \"DURATION\": [] # No specific duration mentioned in the given text.", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" {}\n\"DURATION\": []\n\nThis sentence does not provide any specific duration information. HAART is a chronic treatment.", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" No specific durations were mentioned in the text.\n\n\"DURATION\": []", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"DURATION\": []\n\nThis sentence does not provide any information about the duration of events or treatments. It only mentions the side effects of EFV and NVP and a reference to where this information can be found.", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" \"DURATION\": []", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" \"DURATION\": []", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"DURATION\": []", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" \"DURATION\": []", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" {\"DURATION\": []}\n\nThis passage does not provide any information about durations of events. It only lists the structures of phenolic compounds and their names.", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" \"DURATION\": []", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" {\"DURATION\": []}\n\nThis passage does not provide any information about the duration of events or treatments. It only mentions that the extracts caused a concentration-dependent inhibition in CYP2B6.", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" \"DURATION\": []", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" \"DURATION\": [\"for 72 hours\"]", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" No duration information provided.", {}]], [220, "All authors reviewed the final manuscript.", [" No duration information provided.", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" \"DURATION\": []", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" \"DURATION\": [\"7 \u00b1 1-day\"]", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" It is not clear from the provided text what duration the dose of GGT was applied in the study. Therefore, the \"DURATION\" field should be left empty.", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" \"DURATION\": [\"per day\"]\n\nThis information does not provide information about the duration of the treatment itself, only about the suggested dosing frequency per day.", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" \"DURATION\": [\"in a week\"]", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" \"DURATION\": [\"once a day\", \"4 times a day\"]\n\nIn this case, AAP was administered with two different dosing frequencies, once a day and 4 times a day. The duration of administration was not explicitly stated, but it can be assumed that it was for a certain period of time, as both the test and control groups received the treatment daily in the presence or absence of GGT.", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" I'm unable to determine the duration of a reference to a person's initials, Y.C.P. Please provide more context if possible.", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" I'm unable to extract any information related to durations from the given text. The text only mentions the names of individuals involved in the study.", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" \"DURATION\": []", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" \"DURATION\": [\"long-term\"]\n\nIn this context, \"long-term\" refers to the duration of the supplementation, but an exact duration is not mentioned in the text.", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"DURATION\": [\"prevalent among patients taking prescription medications\"]\n\nIn this context, there is no explicit mention of a specific duration for the surveys or the age of individuals greater than 65 years.", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"DURATION\": [\"\"]\n\nThe text does not provide specific durations for the age-related changes mentioned.", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" \"DURATION\": [\"five days\"]", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" No duration information provided.", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" {}\n\n\"DURATION\": []\n\nThis statement does not provide any information about the duration of events or treatments. It only states that all subjects completed the study without any serious adverse events.", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" \"DURATION\": [\"\"]\n\nThis table does not provide information about the duration of events or treatments. It only presents pre- and post-supplementation phenotypic ratios and their respective confidence intervals for CYP and the supplement.", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" \"DURATION\": [\"when more conventional \u2018area-under-the-curve\u2019 methods were utilized\"]\n\nThis passage does not provide specific durations for events, only that other investigators used \"more conventional \u2018area-under-the-curve\u2019 methods\" in the past.", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" No duration information provided.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" No duration information provided.", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"DURATION\": []", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" \"\"DURATION\"\": [\"\"]\n\nThis text does not provide any information about durations of events.", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" No duration information provided.", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" {}\n\"DURATION\": []\n\nThis sentence does not provide any information about durations of events.", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" No information for \"DURATION\" field.", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"DURATION\": [\"aforementioned reports hint strongly\"] # No specific duration mentioned in the text, but the context suggests that the induction of CYP2C9 by ginseng is a long-term effect.", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" No specific durations mentioned in this statement.", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {}\n\n\"DURATION\": []\n\nThis sentence does not provide any information about the duration of an event or process. It only mentions that blood samples were collected and analyzed for plasma quinine and its metabolite using a validated HPLC method.", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" {\"COMPOUNDS\": [\"benxophenones\", \"xanthones\", \"alkaloids\", \"phenols\", \"tannins\", \"saponins\", \"kolaviron\", \"biflavonoid complex\", \"aluminum\", \"magnesium\", \"calcium\", \"copper\"]}\n\n\"DURATION\": []\n\nNote: The \"DURATION\" field is empty as no duration information was provided in the text.", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" {}", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" No specific durations were mentioned in this text.", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"DURATION\": [\"after an overnight fast\", \"each subject in the respective groups received a single oral dose\"]\n\nThis information does not provide enough context to determine the duration of the study or experiment. The first phase only refers to the administration of a single oral dose of quinine sulphate to each subject.", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" \"DURATION\": [\"just before the administration\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"]", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" \"DURATION\": []\n\nThis information does not provide any duration information. It only mentions the limit of quantitation for quinine and 3-hydroxyquinine.", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" \"DURATION\": [\"\"]\n\nThis information does not provide any duration information. It only states that the AUC0\u2013\u221e of quinine was reduced by about 9%.", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" No duration information provided.", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"DURATION\": [\"in this current study\"]\n\nThe text does not provide specific durations for the interactions between quinine and G. kola or the reduction in Cmax and tmax of quinine.", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"DURATION\": []", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" This statement does not provide any information related to durations of events. Therefore, the \"DURATION\" field should be left empty.", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {\"DURATION\": [\"for the duration of the study\"]}\n\nIn this case, the duration is not explicitly stated, but it can be inferred that it refers to the duration of the study, as the participants were randomized to either the S. frutescens group or the placebo group.", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"DURATION\": [\"\"]\n\n[10] and [11] do not provide specific information about the duration of TCAM use.", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" \"DURATION\": [\"\"]\n\nThis statement does not provide any information about the duration of the study or treatment.", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" \"\"DURATION\": []\"\"\"\n\nIn this sentence, there is no mention of a specific duration of events or experiments.", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" There is no information about durations in this text related to the given abbreviations (HDL and LDL).", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" I cannot directly parse information from a PDF file or a link to a file. The information regarding durations must be extracted from the text provided in the article.", {}]], [265, "Thabethe, D.A.", [" I'm unable to extract any information related to durations from the given text regarding \"Thabethe, D.A.\".", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" {}", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" No specific duration mentioned in the text.\n\n\"DURATION\": []", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" No specific durations were mentioned in this statement.", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" \"DURATION\": []", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" No duration information provided.", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" No duration information provided.", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" No duration information provided.", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or treatments. It only mentions that a study by another researcher reported a trend among middle-aged patients.", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"DURATION\": []", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" {}\n\n\"DURATION\": []\n\nThis information does not provide any duration information. It only mentions a citation.", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" \"DURATION\": []", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" \"DURATION\": [\"2 months after the end\"]", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" {}\n\nNo duration information was found in this text.", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" \"DURATION\": [\"for at least 6 min\"]", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"DURATION\": [\"before and after warfarin dosing\"]\n\nExplanation: The International normalized ratio (INR) was measured at different time points before and after warfarin dosing.", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" \"DURATION\": []", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" \"DURATION\": []", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" \"\"DURATION\": []}\n\nThis passage does not provide any information about the duration of events or processes. It describes a pharmacokinetic and pharmacodynamic modeling approach used in a study.", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" {}", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"DURATION\": [\"NA\": Not Applicable]\n\nThe table provides pharmacokinetic parameters for S-warfarin and R-warfarin under various conditions. The duration-related information includes:\n\n* The study did not report any specific duration for the administration of warfarin or its combinations with cranberry, garlic, or both.\n* The tmax (time to maximum concentration) values are reported in hours.\n* The t1/2 (half-life) values are reported in hours.\n* The AUC (area under the plasma concentration-time curve) values are reported in \u03bcg mL\u22121 h.\n* The CL/F (apparent clearance) values are reported in mL h\u22121.\n* The fraction unbound (fu) values are reported as ratios.\n\nTherefore, no specific duration information is provided in the text, but the data in the table represents the results obtained after an administration of the substances.", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" {\"DURATION\": []}\n\nThis information does not provide any duration information. It is just presenting the location of the parameter estimates for warfarin in a table.", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" \"DURATION\": [\"for 5 days\"]", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (2006b) studied 7 patients with atrial fibrillation.\n\n{\"DURATION\": []}", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" \"DURATION\": []", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" \"DURATION\": []", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" \"DURATION\": []", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"DURATION\": []\n\nThis statement does not provide information about the duration of the event. It is a warning about the potential interaction between valerian and CYP 3A4.", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" There is no specific duration mentioned in the text regarding the elderly being recommended to avoid certain entities.\n\n\"DURATION\": []", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {\"DURATION\": []}", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" \"DURATION\": []", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" \"DURATION\": []", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" \"DURATION\": []", {}]], [298, "[36].", [" This information does not provide any duration details.\n\n{\"DURATION\": []}", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" \"DURATION\": [\"for 14 days\"]", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" \"DURATION\": [\"before the test period\", \"after the test period\"]\n\nNote: It's important to mention that the exact duration of the test period is not specified in the text. However, based on the context, it can be assumed that the activities of the CYP enzymes were determined before and after the administration of the treatment.", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" \"DURATION\": [\"over 12 weeks\", \"beginning after 15 days\"]", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" \"DURATION\": []", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" \"DURATION\": [\"\"]\n\nThis statement does not provide any information about durations of events. It only mentions that the evidence supporting a pharmacodynamic interaction of valerian preparations with other drugs comes from two case reports.", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" \"DURATION\": []", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" \"\"DURATION\"\": []", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" \"\"DURATION\": []\"\"\"\n\nThis statement does not provide any specific duration information. It is discussing the challenges of extrapolating in vitro data to in vivo situations due to the open questions regarding bioavailability and metabolism of extract components.", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" \"\"DURATION\": []\"\"\"\n\nThis statement does not provide any information about the duration of events or treatments. It only states that there is no proven clinical observation of pharmacodynamic interactions at present.", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" \"\"DURATION\": []\"\"\"\n\nThis information does not provide any specific duration information. It only mentions that the safety information regarding interactions for valerian is mentioned in certain monographs and fact sheets.", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" {\"DURATION\": []}\n\nThis information does not provide any specific durations of events.", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" No duration information provided in this statement.", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" No information related to duration in this statement.", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"DURATION\": [\"for 7 days\"]", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" There is no duration information provided for Venlafaxine in this context.\n\n\"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.\"", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" \"DURATION\": [\"after venlafaxine discontinuation\"]", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" No duration information provided.", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" \"DURATION\": [\"from hours to months\"]", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" \"DURATION\": []", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" I'm unable to directly parse the given text as it's in Portuguese and I don't have the ability to understand or translate languages. However, based on the context, it seems to be describing a comprehensive investigation that included LBA (Laboratory Blood Analysis), imaging studies, autoimmune disease detection, right heart catheterization, and myocardial biopsy. Since no specific durations are mentioned, the \"DURATION\" field should be left empty.\n\n{\"DURATION\": []}", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" \"DURATION\": [\"\"]\n\nNote: The text does not provide information about durations of events related to the cited entities in this Portuguese excerpt. The text mentions the administration of CYP2D6 inhibitors and the presence of a slow metabolizer phenotype, but it does not specify for how long these conditions existed before the manifestation of venlafaxine toxicity.", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" I'm unable to parse the given text as it is not in English. However, based on the context, it seems to indicate that the renal, hepatic, complement protein, and urine sediment parameters were all normal. No duration information is provided.", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" I'm unable to parse the given text as it is not in English and does not contain any entities related to durations of events.", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" I'm unable to parse the given text for durations as it's not written in the required format and it's in Portuguese. The text describes a case of a 35-year-old patient who underwent exhaustive investigation after other possible causes were excluded.", {}]], [323, "Apoio financeiro: Nenhum.", [" \"DURATION\": []\n\n(Note: This information is not related to the duration of events or entities in the text.)", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {}\n\n\"DURATION\": []\n\n(This study does not provide specific information about the duration of the study or any events related to the study.)", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"DURATION\": [\"within 1 mo\", \"within 3 mo\", \"within 4 wk\", \"within 6 mo\"]\n\nEntities:\n- women\n- surgery\n- chemotherapy\n- hysterectomy\n- endometrial hyperplasia\n- breast cancer\n- sex hormone\u2013related cancers\n- hypertension\n- diabetes mellitus\n- uncontrolled\n- fasting blood sugar\n- cases\n- medication\n- diabetes\n- thyroid patients\n- severe migraines\n- thromboembolism\n- cerebrovascular disease\n- cardiovascular disease\n- atypical uterine bleeding\n- sleep inducers\n- antidepressants\n- selective estrogen receptor modulators\n- antihyperlipidemic drugs\n- antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel)\n- bisphosphonates\n- calcitonin\n- plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products)\n- functional foods\n- herbal medicines\n- female hormone formulations\n- Alanine aminotransferase (ALT)\n- aspartate aminotransferase (AST)\n- mammographies\n- Pap smears\n- Breast Imaging Reporting and Data System (BI-RADS)\n- clinical trials.", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" \"DURATION\": []", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" \"DURATION\": []", {}]], [328, "p-value by Fisher's exact test.", [" \"p-value\": []\n\nThe text does not provide any information about the duration related to Fisher's exact test.", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" \"\"\n\n\"DURATION\": []\n\nThis information does not provide any duration information related to the entities mentioned.", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" \"DURATION\": []", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" \"DURATION\": [\"for a long period\"]", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" \"DURATION\": [\"\"]\n\nThe text does not provide information about the duration of the inhibition kinetic study or the experiments related to celastrol's inhibition of UGT1A1 and UGT2B7.", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" \"DURATION\": []", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" This statement does not provide any specific duration information. It is a description of the type of inhibition observed in Dixon and Lineweaver-Burk plots.", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {\"DURATION\": []}\n\nThis information does not provide any duration information. It is only reporting the value of the inhibition kinetic parameter (Ki) for celastrol.", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"DURATION\": []", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" There is no specific duration mentioned in the text for the metabolism of clofibric acid and valproic acid by the mentioned entity.\n\nTherefore, the \"DURATION\" field should be left empty.", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" {\"DURATION\": []}", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"DURATION\": []}\n\nThis sentence does not provide information about the duration of any events or treatments. It is about an inhibition kinetic analysis of celastrol towards UGT2B7-catalyzed 4-MU glucuronidation.", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" \"\"DURATION\": []\"\"\"\n\nThis passage does not provide any specific duration information related to the therapeutic benefits of ginseng. It only mentions the studies and references where these benefits have been reported.", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"DURATION\": [\"for one dose\"]\n\nIn this case, the duration is not explicitly mentioned in the text, but it can be inferred that it refers to a single oral dose. The study investigated interactions between Korean red ginseng extract and five cytochrome P450 enzymes in mice.", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" \"DURATION\": [\"\"]\n\n(Note: No specific durations were mentioned in the text regarding the use of valsartan as a model drug for investigating OATP or Oatp-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.)", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or treatments. It only mentions that the results were revealed after the administration of RGE and Rc was repeated and a high dose of valsartan was involved.", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"DURATION\": []\n\nThe text does not provide any information about durations of events related to the plasma concentration and unbound fraction of tri-glycosylated PPD-type ginsenosides.", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" \"DURATION\": [\"for 10 min\"]", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" \"DURATION\": [\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\"]", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" \"DURATION\": [\"after 1-week repeated administration\"]", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" \"DURATION\": [\"from 0 to 48 h\"]", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or treatments. It is a recommendation or requirement for assessing herbal products.", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" \"\"\n\n\"DURATION\": []\n\n\"This statement does not provide information about the duration of an event or treatment.\"", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" \"\"DURATION\": []\"\"\"\n\nThis information does not provide any duration information. It only mentions the number of subjects for the study.", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"DURATION\": []\n\nThis passage does not provide any information about the duration of events or treatments. It only mentions that circulating serum markers are used to measure oxidative stress in PCOS patients.", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" There is no specific duration mentioned in the text regarding the use of the herbal agent for treating PCOS as a disease of antioxidant deficiency.", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" \"\"\n\n\"DURATION\": []\n\n[17] likely reports results from a previous study, but the duration is not explicitly stated in the provided text.", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"DURATION\": []\n\nThe text does not provide any information about durations of events or treatments related to Citrus Sinensis (L.) Osbeck or its bioactive compounds.", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" {\"DURATION\": [\"\"]}\n\nThis sentence does not provide information about the duration of an event or treatment. It only mentions the results of a study that shows hesperidin increases antioxidant levels and decreases MDA level.", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" \"DURATION\": [\"about 4 h\"]", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" \"DURATION\": [\"\"]\n\n[Explanation: The given text does not provide any information about the duration of an event or a process.]", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" \"DURATION\": []\n\nThis text does not provide any information about the duration of events or processes. It only mentions the use of statistical methods to describe study variables.", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" \"DURATION\": []", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" \"\"DURATION\": []}", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or treatments. It is discussing the relationship between polyphenols and antioxidant activity in medicinal plants.", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" \"DURATION\": [\"\"]\n\nThe text does not provide information about the duration of the study or experiment related to the increase in SOD, CAT, and GPx levels or the significant decrease in MDA level mentioned in reference [17].", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"DURATION\": [] # No specific duration mentioned in the text.", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" There is no clear duration mentioned in the text for the study or experiment related to spearmint and its phenolic phytochemicals. Therefore, the \"DURATION\" field should be left empty.", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"DURATION\": [\"\"]\n\nThis sentence does not provide information about the duration of an event or treatment. It only mentions that there is a significant reduction of insulin tolerance and glucose levels after the administration of PMFs.", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" No duration information provided in this sentence.", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" \"DURATION\": [\"in a longer follow-up\"]", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" The term \"PCOS patients\" refers to a patient group and does not have a specific duration associated with it. Therefore, there is no need to include it in the \"DURATION\" field.", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" No duration information provided.", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" \"DURATION\": [\"at the end of the dosing interval\"]", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" This text does not provide any information related to durations of events. It only mentions the name and location of a specific pharmaceutical company (Arkopharma) and a product identifier (V05895B).", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" \"DURATION\": [\"on days 0, 14, and 28\"]", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" This text does not provide any specific durations of events. Therefore, the \"DURATION\" field should be left empty.", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" No duration information provided.", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" \"DURATION\": []", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" I cannot directly extract the duration information from the term \"Darunavir pharmacokinetics\" as it does not specify a particular duration. Pharmacokinetics refers to the study of the absorption, distribution, metabolism, and excretion of drugs in the body.", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"DURATION\": [\"\"]\n\nThis information does not provide any specific duration information related to the events mentioned. The pharmacokinetic parameters, C\u03c4 and AUC\u03c4, are calculated values that do not have a duration associated with them.", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"DURATION\": [\"after multiple-dose administration\"]", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" \"\"DURATION\"\": []", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" \"DURATION\": []", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" No information for \"DURATION\" field.", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" \"DURATION\": []", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" No duration information provided.", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" \"DURATION\": [\"for 8 days\"]", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" In this context, no clear duration information is provided. Therefore, the \"DURATION\" field should be left empty.", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" \"\"\n\n\"DURATION\": []\n\n\"This sentence does not provide any information about the duration of events or processes.\"", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" \"DURATION\": [\"b.i.d.\", \"\"]\n\nExplanation: The given information does not provide enough context to determine the duration of administration. \"b.i.d.\" stands for \"bis in die,\" which means \"twice a day.\" However, the duration of this administration is not explicitly stated in the given text.", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" \"DURATION\": [\"1 week\", \"sufficient to eventually induce CYPs\", \"was reached\"]", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or processes. It only states that the metrics used for CYP1A2 and CYP2C9 are considered as fully validated.", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" \"DURATION\": [\"over an 8-day period\"]", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {}\n\n\"DURATION\": []\n\nThis study aimed to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials. No specific duration information was provided in the given context.", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {}\n\"DURATION\": []\n}\nThis article does not provide information about durations of events. It is a systematic review of clinical data from randomized controlled trials (RCTs) and a discussion of interactions between herbal medicines and warfarin.", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" I'm unable to parse the duration from the given text as it does not provide specific information about the duration of the PubMed search strategy.", {}]], [395, "Type of participant.", [" The given text does not provide information about the type of participants involved in the studies mentioned.", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" No duration information provided.", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that the study selection and data extraction were done for a certain period of time, but the length of that period is not specified.", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that Table 2 summarizes extraction and formulation method, composition, and bioanalytical data.", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" \"DURATION\": [\"reported information regarding attrition\", \"seven trials\"]\n\nNote: In this context, \"attrition\" refers to the loss of participants from a study, and \"detailed information\" implies that the duration of the studies is not explicitly stated but can be inferred from the context.", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" This information does not provide any duration of events.", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"DURATION\": []", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" \"DURATION\": []", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" \"DURATION\": []", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" \"DURATION\": [\"\"]\n\nThis statement does not provide any specific duration information. It is discussing the limitations of case reports in general.", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" {\"DURATION\": []}", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"DURATION\": [\"in a dose-dependent manner\"]\n\n(Note: No specific duration mentioned for the study, but the information provided refers to the relationship between the dose and the effect on CYP enzyme activity.)", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" {\"DURATION\": []}", {}]], [408, "(DOCX) Click here for additional data file.", [" I cannot directly access or parse data from a link or a document file. The information provided in the text of the article is what I can work with.", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"DURATION\": []", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" \"DURATION\": []", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" \"DURATION\": [\"\"]\n\nIn this text, there is no explicit mention of durations for the diagnostic considerations.", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" \"\"\n\n\"DURATION\": []\n\n\"\"\n\nThis information does not provide any duration information. The Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment. This is an administrative process and does not involve any specific duration of the study or experiments.", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" \"DURATION\": [\"on every study day\"]", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" \"DURATION\": [\"\"]\n\n(No specific duration information was provided in this text.)", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" No specific duration mentioned in the text.\n\n\"ALL\": []", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"DURATION\": []", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" \"DURATION\": [\"\"]\n\nIn this case, no specific durations are mentioned in the text.", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" \"DURATION\": [\"could provide further insight\"] (This information does not specify a duration, but it implies that the studies using alternate designs would likely last longer than the initial study.)", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" No specific durations mentioned in the text.\n\n\"Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.\"\n\nTherefore, the \"DURATION\" field is empty.", {}]], [420, "Supporting Information Click here for additional data file.", [" I cannot directly parse information from a \"Click here for additional data file\" link as it requires accessing external data.", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" No duration information provided.", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" \"DURATION\": [\"3 hours\", \"4 hours\", \"6 hours\", \"8 hours\", \"10 hours\", \"12 hours\"]", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" No specific duration mentioned in the text.", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" {\"DURATION\": []}\n\nThis information does not provide any durations of events.", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or treatments. It only mentions that CBZ (Carbamazepine) has pharmacokinetic properties that make it prone to interaction with coadministered substances.", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" \"DURATION\": []", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" \"DURATION\": [\"(2005\u2013Dec.)\"]\n\nThis information refers to the time period covered by the Cochrane Database of Systematic Reviews. It is not directly related to the duration of any specific study or experiment mentioned in the text.", {}]], [428, "2012).", [" This is a citation and does not provide information about duration.", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" \"DURATION\": [\"in rabbits\", \"in human\"]\n\nNote: Since the information provided does not specify a particular duration for the studies in humans, it is assumed that the duration is not mentioned in the given context.", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"DURATION\": [\"in rats\", \"in two children\"]\n\nNote: Since the information provided does not specify a consistent duration for the interactions between the dietary supplements and CBZ, the \"DURATION\" field is left as is to reflect the varying durations mentioned in the text.", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" \"DURATION\": [\"long-term basis\"]", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" \"\"DURATION\": []", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"DURATION\": []\n\nThis information does not provide any specific duration information. It only mentions the databases used for the study.", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"DURATION\": [\"\"]\n\n(Note: No specific duration information was provided in the text.)", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" No duration information provided.", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" \"DURATION\": [\"in patients with major depression or bipolar disorder\"]\n\n(Note: No specific duration mentioned in the text)", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" I cannot directly extract the duration information from the given text as it does not provide any specific duration related to the composition of individual herbs in the included herbal formulae.", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" \"DURATION\": []", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" No specific durations mentioned in this text.", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" \"DURATION\": []", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" I cannot directly parse the information from the text into a format for the given key, as there is no specific duration information provided in the text regarding Table 1. However, it can be assumed that the data in Table 1 represents the background characteristics of the patients who were interviewed in the study.", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" No specific duration mentioned in this statement.", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" \"DURATION\": []", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"DURATION\": []", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" \"DURATION\": []", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or treatments. It is about the awareness and monitoring of herbal medicines by healthcare practitioners, which does not have a specific duration associated with it.", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" No specific durations were mentioned in the text.\n\n\"Herb\u2013drug interactions\" refers to the potential negative effects that can occur when using both herbs and drugs simultaneously. No duration information was provided in the text.", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" No specific durations mentioned in the text.\n\n\"DURATION\": []", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"DURATION\": []\n\n[5,6,7] are references and do not provide information about the duration of events or treatments.", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" \"DURATION\": [\"approximately 15 min\"]", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" {}\n\n\"DURATION\": []\n\n(This line does not provide any information about durations of events.)", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {}\n\n\"DURATION\": []\n\n(No duration information was provided in the text.)", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" No duration information provided.", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" No information found for \"DURATION\" field.", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" \"DURATION\": []", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" {\"DURATION\": []}", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {}\n\n\"DURATION\": []\n\n(This sentence does not provide any information about durations of events.)", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" No duration information provided.", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" {}\n\n\"SIGNIFICANCE\": [\"p < 0.01\", \"p < 0.001\"]\n}\n\n\"DURATION\": []\n}\n\nPlease note that the \"SIGNIFICANCE\" field indicates the p-values for statistical significance between the control group and the specified group. The \"DURATION\" field remains empty as no duration information is provided for this statement.", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" \"DURATION\": []", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" \"\"DURATION\"\": [\"\"]\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions the method used to quantify inhibition of cytochrome P450 enzymes and drug transporters.", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" \"DURATION\": []", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"DURATION\": []\n\nThis information does not provide any durations of events. It only states the percentage of inhibition for specific concentrations of Samento and Banderol on CYP3A4 and CYP2C19 enzymes.", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"\"DURATION\"\": [\"\"]\n\nThis passage does not provide any information about durations of events. It only mentions the testing of Samento's effect on the aryl hydrocarbon receptor (AhR) and the comparison with the positive control omeprazole.", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {}\n\"DURATION\": []\n}\n\nThis study focused on in vitro analysis of Samento and Banderol's ability to inhibit activity or induce expression of significant drug metabolizing enzymes and transporters.", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"DURATION\": []", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that a method used to test BCRP inhibition was described previously in a different scientific article.", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" \"DURATION\": []", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" {\"DURATION\": []}", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" \"\"DURATION\": []\"\"\"\n\nThis passage does not provide any information about the duration of events or processes. It only describes the methods used to isolate RNA and synthesize cDNA.", {}]], [471, "Data were evaluated as described previously [28].", [" No specific duration mentioned in this sentence.", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" No duration information provided in this statement.", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" \"DURATION\": []", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" This information does not refer to a duration of an event. It is a statistical significance measure.", {}]], [475, "Results of the reporter gene assays.", [" \"DURATION\": []", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" {\"DURATION\": []}\nThis statement does not provide any information about the duration of an event or treatment. It only mentions a concentration-dependent effect.", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"DURATION\": [\"after four days\"]", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"DURATION\": [\"in LS180 cells\"]", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" \"\"DURATION\"\": [\"to 0\"]\n\nThis information does not provide any duration information related to the treatment or experiment. The RT-PCR analysis was used to quantify the expression of CYP2J2 mRNA and the results were normalized to \u03b22mg and to a time point of 0.", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" \"DURATION\": []", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" {}", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" No specific durations were mentioned in this text.", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"DURATION\": []\n\n{\"Ingredients\": [\n\"Bovis Calculus\",\n\"Dioscoreae Rhizoma\",\n\"Glycyrrhizae Radix et Rhizoma\",\n\"Ginseng Radix\",\n\"Typhae Pollen\",\n\"Massa Medicata Fermentata\",\n\"Glycine Semen Germinatum\",\n\"Cinnamomi cortex\",\n\"Paeoniae Radix\",\n\"Liriopis Tuber\",\n\"Scutellariae Radix\",\n\"Angelicae Gigantis Radix\",\n\"Saposhnikoviae Radix\",\n\"Atractylodis Rhizoma Alba\",\n\"Bupleuri Radix\",\n\"Platycodonis Radix\",\n\"Armeniacae Semen\",\n\"Poria Sclerotium\",\n\"Cnidii Rhizoma\",\n\"Civet\",\n\"Antelopis Cornu\",\n\"Borneolum\",\n\"Ampelopsis Radix\",\n\"Zingiberis Rhizoma\"\n]\n}", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" \"DURATION\": [\"for 2 weeks before and during the study period\"]", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that CYP2B6 genotyping was performed using a previously described method.", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" \"DURATION\": []", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" \"\"DURATION\": []\"\"\"\n\nThis information does not provide any duration information. It is just stating the operating conditions for the TurboIonSpray interface.", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of an event or process. It only mentions the version number of a software used for data processing.", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" \"DURATION\": []\n\nThis information does not provide any specific duration information. It only mentions that geometric means were calculated for various parameters of bupropion and 4-hydroxybupropion.", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" No specific duration mentioned in the text.", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" \"\"\n\n\"DURATION\": []\n\n\"This statement does not provide any information about the duration of events or observations.\"", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" \"DURATION\": []", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" No specific durations were mentioned in the text.", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that tyrosine kinases can be overexpressed or mutated in malignancies.", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"DURATION\": [\"respectively\"]\n\n\"DURATION\": [\"as compared to DAS alone\"]\n\n\"DURATION\": []\n\nThe given text does not provide any explicit duration information. However, it mentions that the inhibition of the Pgp/MDR1 protein was compared to DAS alone, which implies that the measurements were likely taken after the treatment with APG. Therefore, it can be assumed that the inhibition was measured after an appropriate duration post-treatment, but the exact duration is not specified in the text.", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {}\n\"DURATION\": []\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that the inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" \"DURATION\": [\"respectively\"]\n\n\"DURATION\": [\"as compared to DAS only\"]\n\nNote: It is assumed that the inhibition percentages refer to the duration of the experiment or the time point of measurement. However, without further context, it is difficult to determine the exact duration. If the context suggests that the inhibition percentages are constant throughout the experiment, then no duration information is needed. If the inhibition percentages change over time, then the duration of the change should be provided. In this case, without further context, it is not possible to determine the duration based on the given information.", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" \"\"DURATION\": []\"\"\"\n\nThis statement does not provide any specific duration information. It is discussing a general mechanism of herb-drug interactions.", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" {}\n\n\"DURATION\": []\n\nThis sentence does not provide any information about durations of events. It is about the purpose of a study.", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" I cannot directly extract the duration information from the given text. However, I can infer that the pharmacokinetic parameters were altered after administering DAS at a dose of 25 mg/kg orally. No specific duration was mentioned in the text.\n\nTherefore, the \"DURATION\" field should be left empty for this entry.", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" \"DURATION\": [\"one week prior to experiment\", \"12 h\"]", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" \"DURATION\": [\"for 7 days\"]", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" \"DURATION\": [\"on the 7th day\", \"for 7 days\"]", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" No duration information provided.", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" \"DURATION\": []", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" I'm unable to determine the duration of the mention of \"M.A.A.\" in the context provided.", {}]], [507, "; supervision, K.M.A.", [" I cannot extract any duration information from this text. It only mentions the name of a person, K.M.A., who is likely involved in the supervision of the study.", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" This statement does not provide any information related to durations of events.", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" No duration information provided.", {}]], [510, "All results are presented as the average \u00b1 SD.", [" {}\n\n\"DURATION\": []\n}\n\nThis line does not provide information about the duration of any events. It only states that the results are presented with their standard deviation.", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of events or treatments.", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"\"DURATION\"\": [\"\"]\n\n(No specific duration information was provided in the text.)", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" No specific duration mentioned in the text.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" No specific duration mentioned in the text.", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {}\n\n\"DURATION\": []\n}\n\nThis study aimed to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women. No specific duration information was provided in the text.", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {}\n\"DURATION\": []\n}\n\nThis information does not provide any specific duration information.", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {}\n\n\"HYPOTHESIS\": [\"that the supplementation of SC extract in humans can increase muscle strength\"]\n\n\"DURATION\": []\n\nThis information does not provide any duration related to the hypothesis.", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" \"DURATION\": [\"2 min\"]", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" No duration information provided.", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {}", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" \"DURATION\": []", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" \"DURATION\": []", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" \"DURATION\": [\"after 12 weeks\"]", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" \"\"DURATION\"\": [\"\"]\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that there is an association between high lactate production and reduced oxidative metabolism, as reported in a previous study.", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"DURATION\": [\"about 20 years ago\"]", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" No duration information provided.", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" This statement does not provide specific durations of events or treatments. Therefore, the \"DURATION\" field should be left empty.", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" \"DURATION\": [\"in vitro\", \"in vivo\"]", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"DURATION\": [\"in this test\"]\n\n(Note: The duration of the tail suspension test itself is not specified in the text.)", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"\"DURATION\": []}\n\nThis passage does not provide any specific duration information. It describes the function of the PXR gene in drug metabolism and its mechanism of action.", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"DURATION\": []", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" \"DURATION\": [\"before the publication of another comprehensive pharmacokinetic interaction study\"]\n\nIn this context, the duration refers to the time before the reference [Zahner et al., 2019] was published.", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" \"DURATION\": []", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" \"DURATION\": [\"have been performed\"]", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" I cannot make assumptions about the content of the control group in the study you provided. The information given only mentions the control group as receiving vehicle treatment. To accurately parse the entities, I can only consider the information explicitly stated in the text.", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {}\n\n\"DURATION\": []\n\n(This line is left empty as no duration information is provided in the text.)", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"DURATION\": [\"for a period of time\", \"in preclinical studies\", \"dose-related or time-dependent\"]\n\nEntities:\n- T cells\n- caspase 3 activity\n- Bax expression\n- CD4, CD8\n- symptomatic relief\n- appetite\n- WBC (White Blood Cells)\n- platelets\n- cytotoxic drugs\n- tumor inhibition effect\n- survival time\n- immunosuppression\n- phagocytic activity\n- antibody production\n- delayed hypersensitivity\n- cell cycle arrest\n- caspase 3 and 8 expression and activity\n- 5-FU (5-Fluorouracil)\n\n\"DURATION\": [\"increase\", \"decrease\", \"greater recovery rate\"]\n\nPlease note that the exact duration for each effect is not mentioned in the text.", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" \"DURATION\": [\"reduced tumor recurrence\", \"reduced metastasis\"] (No specific duration mentioned in the text)", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" {\"DURATION\": []}\n\nThis information does not provide any specific durations of events.", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" \"\"DURATION\": [\"via\"]}\n\n\"DURATION\": [\"recently\", \"in a study\"]\n\n\"DURATION\": [\"may be due to\", \"for inducing dysbiosis by paclitaxel\"]\n\n\"DURATION\": [\"for down-regulating Warburg-related proteins\"]\n\n\"DURATION\": [\"in the study\"]\n\n\"DURATION\": [\"found\"]\n\n\"DURATION\": [\"such synergistic effect\"]\n\n\"DURATION\": [\"for inhibiting tumor metabolism\"]\n\n\"DURATION\": [\"restoration of the gut dysbiosis\"]\n\n\"DURATION\": [\"induced by paclitaxel\"]\n\n\"DURATION\": [\"for down-regulating Warburg-related proteins\"]\n\n\"DURATION\": [\"in the study\"]\n\n\"DURATION\": [\"may be due to\"]\n\n\"DURATION\": [\"for inducing dysbiosis by paclitaxel\"]\n\n\"DURATION\": [\"for down-regulating Warburg-related proteins\"]\n\n\"DURATION\": [\"in the study\"]\n\n\"DURATION\": [\"found\"]\n\n\"DURATION\": [\"such synergistic effect\"]\n\n\"DURATION\": [\"for inhibiting tumor metabolism\"]\n\n\"DURATION\": [\"restoration of the gut dysbiosis\"]\n\n\"DURATION\": [\"induced by paclitaxel\"]\n\n\"DURATION\": [\"for down-regulating Warburg-related proteins\"]\n\n\"DURATION\": [\"in the study\"]\n\n\"DURATION\": [\"may be due to\"]\n\n\"DURATION\": [\"for inducing dysbiosis by paclitaxel\"]\n\n\"DURATION\": [\"for down-regulating Warburg-related proteins\"]\n\n\"DURATION\": [\"in the study\"]\n\n\"DURATION\": [\"found\"]\n\n\"DURATION\": [\"such synergistic effect\"]\n\n\"DURATION\": [\"for inhibiting tumor metabolism\"]\n\n\"DURATION\": [\"restoration of the gut dysbiosis\"]\n\n\"DURATION\": [\"induced by paclitaxel\"]\n\n\"DURATION", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"DURATION\": [\"in cancer cells\"]}\n\nNote: The given text does not provide specific durations for the mentioned events, but it is assumed that they occur within the context of the study or research being discussed.", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" I cannot determine the duration from the given context \"a\". Please provide more context for accurate parsing.", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" \"DURATION\": []\n\nEntities: T-box protein expressed in T cells (T-bet), GATA-3, transcription factors, T helper cell balance, Bax, caspase 3, T cell apoptosis, Forkhead box protein 3 (Foxp3), programmed death 1 (PD-1.\n\nNo specific durations mentioned in the text.", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" No specific durations mentioned in this summary statement.", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" I cannot directly parse information from a table. However, if the table contains data related to durations of events, please provide the specific data from the table and I will update the \"DURATION\" field accordingly.", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" This statement does not provide any information related to durations of events. Therefore, the \"DURATION\" field should be left empty.", {}]], [547, "Not applicable.", [" {}", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" No specific durations mentioned in the text.\n\n\"DURATION\": []", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"DURATION\": [\"early stage\", \"metastatic\"]\n\nNote: No specific duration information was provided for hormonal therapy in the text.", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"DURATION\": [] # No specific duration mentioned in the text.", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" No duration information provided.", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" No duration information provided.", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" 1), with IC50 values of 1.2 \u00b5M and 0.8 \u00b5M, respectively, after 48 hours of exposure.\n\n\"\"DURATION\"\": [\"after 48 hours\"]\n\nThe IC50 values represent the concentration at which 50% of the cells are inhibited.", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" \"DURATION\": []", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"DURATION\": [\"long-term\"]", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"DURATION\": []", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" I cannot extract information from a figure or its file name. Figure S2 likely refers to a supplementary figure in the scientific article.", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"DURATION\": [\"\"]\n\nThis information does not provide any duration information as it is only describing the range of concentrations of Quinidine used in the in vitro inhibition profiles of CYP2D6 by Dextromethorphan.", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" This statement does not provide any information related to durations of events.", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" \"DURATION\": []", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" \"DURATION\": [\"for 30 minutes\"]", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" \"DURATION\": [\"for two weeks\"]", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" {}", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" {\"DURATION\": [\"1.0 mL\"]} or {\"DURATION\": [\"\"]} (if the duration is not relevant in this context)", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" \"DURATION\": []", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" {\"DURATION\": []}", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of an event or treatment. It only mentions the use of a derivatization agent in an experiment.", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" \"DURATION\": []", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" {\"DURATION\": [\"\"]}\n\nThis sentence does not provide any information about the duration of an event.", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" \"DURATION\": [\"two weeks\"]", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" This is a citation and does not provide information about durations.", {}]], [572, "2016).", [" This is a citation and does not provide information about duration.", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" No specific durations were mentioned in this sentence.\n\nTherefore, the \"DURATION\" field should be left empty.", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" {}\n\n\"MANUFACTURER\": [\"Agilent Technologies\"]\n\"LOCATION\": [\"Palo Alto, CA, USA\"]\n\"EQUIPMENT\": [\"Agilent 1290 series liquid chromatography system\"]\n\n\"DURATION\": []\n\nNote: Since no duration information was provided in the text, the \"DURATION\" field is left empty.", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" \"\"DURATION\": []}\n\nThis information does not provide any duration information. It only mentions that a statistical analysis was performed using Student's paired t-test.", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {}\n\n\"DURATION\": []\n\nThis sentence does not provide any information about the duration of events or treatments. It only suggests an interaction between two entities (GLT and AC) when they are co-administered.", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" Understanding the effect of different durations of treatment on the outcomes of various pharmacological interventions can provide valuable insights for clinical practice and translational science. This information can help clinicians make informed decisions regarding the length of treatment for specific conditions, as well as identify potential risks or benefits associated with longer-term use. Additionally, it can guide researchers in designing and interpreting studies, ensuring that appropriate timeframes are considered when evaluating the efficacy and safety of new therapeutic agents. Overall, a better understanding of the impact of treatment duration on clinical outcomes can lead to improved patient care and more effective drug development.", {}]], [578, "(n\u00a0=\u00a06).", [" This information does not provide any duration information. It is the number of rats in each group.", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" No duration information provided in this sentence.", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" I cannot extract any information related to durations from the given text as it only contains authors' names.", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" I cannot extract any information related to durations from the given text as it only contains authors' names.", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" No duration information provided.", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" \"DURATION\": [\"during pharmacodynamic study\"]", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"DURATION\": []\n\nEntities:\n- EJ (functional foods)\n- Several research groups\n- 12 weeks\n- anthocyanins\n- flavonoids\n- gliptins\n- dipeptidyl peptidase-4 (DDP-4)\n\nNo specific duration information provided for the entities mentioned in the text.", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {}", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" {}", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" \"DURATION\": [\"after seven days\"]", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" No duration information provided.", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" No duration information provided.", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" I cannot determine the duration from the given information \"3a and b\". Please provide more context for accurate parsing.", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" \"DURATION\": []\n\nThis information does not provide any duration information. It only mentions the retention times (minutes) for SITA and PRM in mass chromatograms.", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" There is no specific duration mentioned in the text.\n\n\"Underlying mechanism of diabetes\" refers to a chronic condition, and \"contributes to liver damage\" implies a long-term process. However, no exact durations are provided for these processes in the text.", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" This information does not provide any duration details. Therefore, it should not be included in the \"DURATION\" field.", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" This information does not provide any duration data. It only indicates statistical significance.", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" 1), AST, and ALT (Figs. [2] and [3]) in rats with CCl4-induced liver injury after 7 days of treatment.\n\n\"DURATION\": [\"after 7 days\"]", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" I cannot directly parse information from a table reference (Table 2 in this case). To parse the table, please provide the table data or location where the table can be found.", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" This information does not provide any duration data. It only indicates statistical significance.", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {}\n\"DURATION\": []\n\nThis sentence does not provide any information about the duration of events or treatments. It only states that the results of the study clarified that oral administration of A. officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"DURATION\": [\"in the excretion study\"]", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" \"\"\n\n\"DURATION\": []\n\n\"This statement does not provide any information about the duration of an event or process.\"", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of events or treatments.", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" \"DURATION\": [\"0\u20131 h\", \"1\u20132 h\", \"2\u20133 h\", \"3\u20134 h\", \"4\u20135 h\", \"5\u20136 h\", \"6\u20137 h\"]", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" \"DURATION\": [\"0\u20136 h\", \"6\u201318 h\", \"18\u201328 h\"]", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" \"DURATION\": []\n\nThis passage does not provide any information about the duration of events or processes. It only mentions that the method was validated in compliance with USFDA guidelines, which does not have a specific duration associated with it.", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" No specific duration mentioned in the text.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" {\"DURATION\": []}\n\nThis sentence does not provide any specific duration information. It only mentions that the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups are similar to those in the model group, as shown in Fig. [Therefore, no duration information should be added in this case.]", {}]], [607, "1).", [" I'm assuming you're asking for the duration mentioned in the first text snippet. It is \"for 7 days\" for the multiple RGE group and \"for 6 days\" for the single RGE treatment group.\n\nSo, the output would be:\n\n{\"DURATION\": [\"for 7 days\", \"for 6 days\"]}", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"DURATION\": [\"on a maintenance daily dose\", \"monthly\"]", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"DURATION\": [\"occasionally\"]\n\nNote: In this context, \"occasionally\" refers to the frequency of alcohol intake during anticoagulant therapy, rather than a specific duration of time. However, since the question asked for durations, I have provided the best approximation based on the given information.", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" There is no specific duration mentioned for the use of other herbs (Danshen, Ginkgo biloba, Dong quai, etc.) in the text.", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"DURATION\": [\"daily diet\"]", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"DURATION\": [\"\"]\n\n(Note: No specific duration information was provided in the text.)", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"DURATION\": [\"for 3 days\"]", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {}", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" {\"DURATION\": []}\n\nThis information does not provide any specific duration information. It only states that the ethics committee approval number is 2015KY002.", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" \"DURATION\": [\"\"]\n\n(No specific duration mentioned in the text)", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"DURATION\": [\"possibly because they are found in high relative quantities in aqueous extracts\"] (This refers to the presence or abundance of the mentioned compounds in the extract, not a specific duration of an event.)", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" \"DURATION\": []\n\nThis sentence does not provide any information about the duration of events or treatments. It only mentions that there is a comparison between deeper red calyxes and lighter red or white varieties in relation to antioxidant activity.", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" I'm assuming you're referring to the subsection 7.2 in the article. In this section, the authors mention that they investigated the effect of RGE on P-gp expression in rats. The study involved three groups: control, single RGE treatment, and multiple RGE treatments. The rats in the multiple RGE group received RGE suspension for 7 days, while rats in the single RGE treatment group received water for 6 days followed by RGE suspension on day 7. The results showed that muscle strength improved by 7.7% in humans after 12 weeks of SC extract supplementation.\n\nBased on this information, the following entities and their corresponding durations can be identified:\n\n{\"DURATION\": [\"for 7 days\", \"for 6 days\", \"for 12 weeks\"]}\n\nEntities: control, single RGE treatment, multiple RGE treatments, RGE suspension, water, 12 weeks, 7 days, 6 days.", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" \"DURATION\": [\"\"]\n\nThis information does not provide any specific duration information related to the experiments or interventions. It is just a title of a table that lists the results of cholesterol RCT interventions and their effects on total cholesterol, HDL-C, LDL-C, and triglycerides.", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" \"DURATION\": [\"for 15 days\"]", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" \"DURATION\": []", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"DURATION\": []\n\n[\"IN VITRO\", \"IN VIVO\"]\n\n\"MECHANISMS\": [\n\"vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx\",\n\"ACE inhibition\",\n\"by the stimulation of new vessel formation and a reduction of myocardial mass or anthocyanins competing with the substrate for the active site\",\n\"decrease in blood viscosity through cyclooxygenase inhibitory activity\",\n\"inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway\"\n]", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" \"DURATION\": [\"at lower doses\"]\n\n\"DURATION\": [\"extremely high doses\"]\n\nNote: The given text does not provide enough information to determine the exact duration for the hepatotoxic effects.", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" No duration information provided.", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" No information related to duration in this sentence.", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" \"DURATION\": []", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" {\"DURATION\": []}\n\nThis statement does not provide information about the duration of any events or treatments. It only mentions a predicted increase in bosutinib systemic exposure with S. sphenanthera at a clinically-relevant dose.", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" \"DURATION\": [\"extensively used\"]\n\n\"SUBJECT\": [\"drug metabolism\", \"herb\u2013drug interactions\", \"modelling and simulation\", \"physiologically-based pharmacokinetic (PBPK)\"]\n\n\"ALREADY\\_KNOWN\": [\"Physiologically-based pharmacokinetic (PBPK) modelling approaches have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.\"]", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" {}\n\n\"DURATION\": []\n\nThis sentence does not provide any information about the duration of events or processes. It is a statement expressing the need for a reliable and systematic approach to predict herb-drug interactions.", {}]], [631, "Go to: 2.", [" I assume you are asking for the information related to the second reference [123] in the text. Here's the information related to the duration from that reference:\n\n\"Animal model experiments, surveys, and small pilot studies show potential benefits in IBD treatment over short periods (8 weeks), while longer use (6 months) is associated with a higher rate of surgery (reviewed in [123]).\"\n\n\"DURATION\": [\"8 weeks\", \"6 months\"]\n\nThis information is already provided in the previous response, but I will include it here for completeness.", {}]], [632, "2.1.2.", [" I cannot determine the duration from the given text fragment \"2.1.2.\" as it does not contain any information about durations of events.", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" \"DURATION\": [\"\"]\n\n(This passage does not provide any information about the duration of events or processes.)", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" \"DURATION\": [\"placing the tubes on a cooling block\"]\n\nThis information does not provide a clear duration for the reaction, but it indicates that the reaction is terminated by placing the tubes on a cooling block.", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" \"\"DURATION\"\": []", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" \"DURATION\": []", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" \"DURATION\": []", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" \"DURATION\": []", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" \"DURATION\": []", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" \"DURATION\": [\"as detailed in Table 3\"] (Assuming Table 3 refers to the design or duration of the trial)", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or extract information from an external file. However, if the file contains information such as durations, please provide the information in the text of the article.", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" I'm unable to extract any information related to durations from the given text \"Go to: 4. MBI, mechanism-based inhibition\".", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"DURATION\": [\"from a chronic exposure\"]", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" \"DURATION\": []", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"DURATION\": [\"in vitro\"]", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" There is no specific duration mentioned in the text regarding the use of Ginkgo biloba or the occurrence of haemorrhage. Therefore, the \"DURATION\" field should be left empty.\n\n{\"DURATION\": []}", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"DURATION\": []", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" \"DURATION\": [\"\"]\n\nThis information does not provide any specific durations of events. It only mentions the methods used in the study to investigate the activity, mRNA expression, and protein expression of CYP, VKOR, and TM.", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"DURATION\": [\"for pharmacodynamic analysis\"]\n\nThis information does not provide specific durations for events, only the context of the analysis.", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" {}\n\n\"DURATION\": []\n\nThis sentence does not provide any information about durations of events. It only mentions the year of a reference and the method used for herb authentication.", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" \"DURATION\": []", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" \"DURATION\": [\"total running time of 90 min\", \"for 5 min\", \"for 13 min\", \"for 12 min\", \"for 10 min\", \"for 30 min\", \"for 5 min\", \"for 15 min\"]", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" \"DURATION\": []", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" \"\"DURATION\"\": [\"\"]\n\n(No specific duration mentioned in the text)", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" This information does not provide any duration of events. It only indicates the statistical significance of the results compared to the vehicle control group.", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" {\"DURATION\": []}\n\nThis passage does not provide any specific durations of events. It only mentions the effects of Danshen, Gegen, and warfarin without specifying the duration of these effects.", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" \"DURATION\": []\n\n(No specific duration mentioned in the text)", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" No specific duration mentioned in this statement.", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"DURATION\": [\"in humans\"]\n\nAdditionally, there were no reports in the literature regarding interactions between Gegen (SC extract) and warfarin, but several case reports suggested interactions with Danshen (another component of the same herb).\n\n\"DURATION\": [\"\"]\n\n(Note: Since the interaction reports were related to Danshen and not explicitly mentioned for Gegen, the \"DURATION\" field is left empty.)", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"ENTITIES\": [\"CYP enzymes\"], \"DURATION\": []", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"DURATION\": []", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" \"DURATION\": [\"\"]\n\n(Note: No specific duration information was provided in the text.)", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that certain compounds were found in extracts of Danshen.", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", ["\"DURATION\": [\"in vitro\", \"in vivo\"]}", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" No specific durations were mentioned in this text.", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" \"DURATION\": []", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" \"DURATION\": []\n\nThe text does not provide any information regarding durations of events or treatments related to the entities mentioned.", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" \"DURATION\": []", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" {\"DURATION\": []}\n\nThis information does not provide any duration information. It only mentions the authors of a publication.", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" \"\"DURATION\": []\"\"\"\n\nThis sentence does not provide any information about the duration of events or processes.", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" No information found for \"DURATION\" field.", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" \"DURATION\": [\"mean of 37 months\", \"range 4\u2013113\"]", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" \"DURATION\": []", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"DURATION\": [\"supposedly provide cure or offer safe use\", \"this self-medication practice is common among chronically ill patients or patients with terminal diseases\"]\n\nThe text mentions the duration of use for alternative remedies and self-medication practices, specifically mentioning \"for cure or offer safe use\" and \"common among chronically ill patients or patients with terminal diseases\". However, the exact durations are not specified in the text.", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"DURATION\": [\"for the management of chronic diseases\", \"as antimalarials and antimicrobials\"]\n\nThe given text does not provide specific information about the duration of use for each mentioned plant (Alstonia boonei, Bauhinia monandra, and Picralima nitida) in the context of this sentence. However, it is mentioned that they are used in the management of chronic diseases and as antimalarials and antimicrobials, which implies a longer duration of use.", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"DURATION\": []", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" \"DURATION\": []", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" No duration information provided.", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" No duration information provided.", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" \"DURATION\": []\n\nThe text does not provide any information about durations for the cited references.", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" \"DURATION\": []\n\n(This information does not provide any duration information.)", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" \"IC\" (concentration)\n\n\"DURATION\": []\n\nNote: The term \"IC\" refers to the fifty percent inhibitory concentration, but it does not specify a duration in this context.", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" \"DURATION\": [\"conducted for commonly used herbs\"]\n\nNote: In vitro studies do not have a specific duration mentioned in the text.", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" \"DURATION\": []", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" \"DURATION\": []", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" {}\n\n\"DURATION\": []\n\nThis sentence does not provide any information about durations of events.", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" No duration information provided.", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" This is a citation and does not provide any information about duration.", {}]], [689, "(2000).", [" This is likely a citation and does not provide information about duration.", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"DURATION\": []\n\nThe text does not provide information about the duration of specific events or experiments. It discusses the potential in vivo inhibitory activity of Gongronema latifolium and Alstonia boonei on CYP1A2, CYP2C19, and CYP3A4, and the challenges in identifying or quantifying the inhibiting components in the complex mixtures of phytochemicals in the herbs.", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" No duration information provided.", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" \"DURATION\": [\"during the period of transition to menopause\"]", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" I'm unable to extract any information related to durations from this text snippet.\n\n{\"DURATION\": []}", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" I'm unable to extract specific durations from this text as it primarily discusses the approval of an ethics committee protocol without mentioning specific durations related to the study.", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" {}", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" {}\n\nThere is no information regarding durations in this text.", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" \"DURATION\": [\"for 14 days\"]", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" No duration information provided.", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" {\"DURATION\": []}", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" {}", {}]], [701, "A difference was considered significant at P < 0.05.", [" {}", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" \"DURATION\": [\"single oral dose\"]\n\nOr, if more context is needed:\n\n\"DURATION\": [\"after a single oral dose\"]", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" \"DURATION\": []", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" \"DURATION\": []", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" There is no specific duration mentioned in the statement. Therefore, the \"DURATION\" field should be left empty.", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" \"DURATION\": []", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" I cannot directly parse the information from an image file. However, based on the context, the term \"drug interactions\" implies that the duration of the interaction could vary depending on the specific circumstances. Therefore, it is not possible to provide a definitive answer without additional information.", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" No duration information provided.", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"DURATION\": []\n\nThis passage does not provide any information about durations of events. It only mentions the method used for detecting CYP2C9 polymorphisms, which is not a duration.", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" \"DURATION\": []", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"DURATION\": [\"for 2 weeks\"]\n\nAdditionally, the table provides the platelet aggregation results after 2 weeks of treatment for each group and agonist:\n\n* Control group: ADP (7.8 [5.5, 10.0]), Arachidonic acid (11.0 [9.6, 12.5]), Collagen (13.0 [11.5, 14.6])\n* Policosanol treatment group: ADP (6.8 [4.9, 8.8]), Arachidonic acid (11.2 [9.4, 12.9]), Collagen (14.9 [12.6, 17.2])\n* Echinacea treatment group: ADP (7.5 [4.1, 10.8]), Arachidonic acid (12.1 [9.3, 15.0]), Collagen (15.8 [12.2, 19.5])\n\nThe geometric mean ratios to the control group are also provided for each treatment and agonist.", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" \"DURATION\": [\"ranged from\", \"\"]\n\n\"DURATION\": [\"\", \"to\"]\n\n\"DURATION\": [\"\", \"ng ml\u22121\"]\n\n\"DURATION\": [\"Cmax was found to range from\", \"\"]\n\n\"DURATION\": [\"\", \"ng ml\u22121\"]", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" \"\"\n\n\"DURATION\": []\n\n[Note: In this case, no specific duration information was provided in the text.]", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"DURATION\": []\n\nThis is a citation and does not provide any information about the duration of an event or treatment.", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" \"DURATION\": []", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"DURATION\": [\"across all four surveys\"]\n\nThe surveys were conducted at different times, so no specific duration is mentioned for each survey individually. However, the text mentions that the data was collected from \"earlier surveys\" and a \"survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston.\" Therefore, the duration for each survey is not explicitly stated, but it can be inferred that they were conducted over a certain period of time in the past.", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"DURATION\": []", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" \"DURATION\": []", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" \"DURATION\": [\"\"]\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions that IC (inhibition constant) was not determined in vitro CYP assays and that these assays offer an accurate and relatively inexpensive tool for assessing potential herb-drug interactions.", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" \"DURATION\": []\n\nThis passage does not provide any information about durations of events. It only mentions the source of certain compounds used in the study.", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" No duration information provided.", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" No duration information provided.", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" \"\"DURATION\": []}\n\nThis passage does not provide any information about the duration of events or processes. It only mentions the specific instrument and software used for conducting the high resolution LC-MS analysis.", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"DURATION\": []", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" This information does not provide any duration information.", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" \"DURATION\": []", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" No duration information provided.", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" \"DURATION\": [\"\"]\n\nThis information does not provide any specific duration information related to events or treatments. It only mentions that the pharmacokinetic data was analyzed and that curcumin-treated animals had significantly higher values for two specific plasma concentration-related parameters.", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" I cannot determine if the phrase \"Worse than the Disease?\" refers to a specific study or context with defined durations. Please provide more information for accurate parsing.", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or extract information from an external file. However, if the file contains information such as durations, please provide the information in the text of the article.", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" \"DURATION\": [\"five days\"]", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" \"DURATION\": []", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" No specific duration mentioned in the text.", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" No specific durations were mentioned in the text.", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" {}", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" No duration information provided.", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" No duration information provided.", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" \"DURATION\": []", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" \"DURATION\": [\"at 30 min following the 8PM dose on Day 5\"]", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" \"DURATION\": [\"\"]\n\n(Note: No specific duration information was provided in the text.)", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" No specific duration mentioned in the text.", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" \"DURATION\": [] # No specific duration mentioned in the text.", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" \"DURATION\": []", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" 1). The duration of the study or administration of RS is not mentioned in the text.\n\n{\"DURATION\": []}", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" 1).{\"DURATION\": []}\n\nThis sentence does not provide any duration information. It only mentions the presence of a figure.", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" I'm unable to determine the duration from the given context.\n\n\"S8).\" likely refers to a subsection or a figure number in the scientific article.", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" \"DURATION\": []", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" \"DURATION\": [\"in rat plasma\"]", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" No specific durations were mentioned in the text.", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"DURATION\": []", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"DURATION\": [\"-\", \"in rats\"]\n\n\"CL\": []\n\n\"AUC\": []\n\n\"k\": []", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"ENTITY\": [\"Radix Isatidis\", \"Root of Isatis indigotica Fort.\", \"Banlangen\"]", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" {\"NAME\": [\"Fructus Arctii\", \"Fruit of Arctium lappa L.\", \"Niubangzi\"]}", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" \"DURATION\": [\"\"]\n\n(Note: No specific duration information is provided in the text.)", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" {}\n\n\"DURATION\": []\n\nThis conclusion statement does not provide any specific duration information.", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"DURATION\": []", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" There are no durations mentioned in this text. Therefore, the \"DURATION\" field should be left empty.\n\nEntities mentioned:\n- dried orange peel (Citrus aurantium L.)\n- Anemarrhena (Anemarrhena asphodeloides Bunge)\n- Phellodendron bark (Phellodendron amurense Rupr.)", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" There is no mention of durations for the entities: Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)\n\nTherefore, the \"DURATION\" field should be left empty for these entities.", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" \"DURATION\": []", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" \"DURATION\": [\"\"]\n\nThis information does not provide any specific duration information related to the study or treatments mentioned.", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" \"DURATION\": []", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" No duration information provided.", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"DURATION\": [\"in a study involving\", \"when used in combination\", \"to treat TAM-resistant MCF-7/TAM-R cells\"]\n\nNote: No specific duration information was provided in the text.", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {}", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" {}\n\n\"DURATION\": []\n\n(Note: No specific duration information was provided in the text regarding Jiawei Xiaoyao San.)", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" \"\"DURATION\": []\"\"\"\n\nThis statement does not provide any specific duration information. It only indicates that the protective effect is dose-dependent.", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"DURATION\": [\"in rats\"]\n\n\"DURATION\": [\"reported\"]\n\n\"DURATION\": [\"with the study\"]\n\n\"DURATION\": [\"alleviates the oxidative stress status\"]\n\n\"DURATION\": [\"of TAM-intoxicated liver injury\"]\n\n\"DURATION\": [\"significant increase in antioxidant enzymes\"]\n\n\"DURATION\": [\"significant decrease in the activity of sGPT and sGOT\"]\n\n\"DURATION\": [\"reduction of glutathione\"]\n\n\"DURATION\": [\"significant reduction of TBARS and liver transaminases\"]\n\n\"DURATION\": [\"(El-Beshbishy, 2005b)\"]\n\nNote: I assumed that the duration mentioned in the text refers to the study or experiment in this context.", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" \"\"DURATION\": []\"\"\"\n\nThis statement does not provide any information about the duration of events or processes. It is a statement about the limitations of protein expression level monitoring in understanding transcription activity in vitro.", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" \"DURATION\": [] # No duration information provided in the text.", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" \"DURATION\": [\"2000\u20132019\"]\n\nThis information does not provide any specific duration for an event or treatment in the study. It is just mentioning the time frame of a reference.", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"DURATION\": []", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" \"\"DURATION\"\": [\"\"]", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" \"DURATION\": []", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"DURATION\": []", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" \"DURATION\": [\"0\u20138.5 min\", \"8.7\u201311 min\", \"11.5\u201313.5 min\", \"14\u201315 min\"]", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" No duration information provided.", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" \"DURATION\": []", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" \"\"DURATION\"\": [\"\"]\n\nThis sentence does not provide any information about the duration of events or treatments. It only mentions that figures 3 and 4 display the PK changes of GA and PCA, respectively.", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"DURATION\": [\"after intravenous administration\", \"in the absence\", \"in the presence\"]\n\nNote: It is not clear from the context if the \"tissue distribution curves\" refer to a specific duration. If more information is provided in the article, please let me know and I will update the duration information accordingly.", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"DURATION\": [\"after oral administration\"]\n\n\"DURATION\": [\"in the absence\", \"in the presence\"]\n\n\"DURATION\": [\"The tissue distribution curves of PCA are shown in Figures 8A,B, respectively.\"]", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" \"DURATION\": []", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" \"DURATION\": []\n\nThis text does not provide any information about durations of events. It only mentions the funding sources for the study.", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" \"DURATION\": []", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" This statement does not provide any specific duration information.", {}]], [785, "Click here for additional data file.", [" I cannot click on links or access external files as I am just a text-based AI. However, if the data file contains information related to durations of events, please provide the information in the text of the article for me to parse.", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" \"DURATION\": []", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" \"\"DURATION\"\": [\"\"]\n\nThis sentence does not provide information about the duration of any event or treatment. It is describing the setup of a scale used to measure something.", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" \"DURATION\": []\n\nThis information does not provide any duration information. It only compares the total area under the curve (AUC) for two different compounds (CHO and YM) in a study.", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {}\n\"DURATION\": []\n\nThis statement does not provide any information about the duration of events or treatments.", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" \"DURATION\": [\"determined using an incremental protocol\"]\n\nThis information does not provide a clear duration for the exercise intensities study, but it can be inferred that it likely involved a protocol with multiple stages or increments.", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" \"DURATION\": [\"acutely\", \"after 12 weeks\"]", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"DURATION\": [] # The given information does not provide any specific durations.", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" \"\"\n\n\"DURATION\": []\n\n\"Additionally, more research is needed to identify the active components of YM capsules and determine their bioavailability after consumption.\"", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" \"DURATION\": [\"of fat and weight-loss supplementation protocols\"]\n\nThis information does not provide specific durations for events, only the context of the expected outcomes.", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" \"DURATION\": [\"during exercise\"]\n\nAdditionally, \"future research could test the longitudinal YM effectiveness\" suggests a longer duration of study. However, the exact duration is not mentioned in the text.", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" This information does not provide any duration details.\n\nTherefore, the \"DURATION\" field should be left empty.", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" No duration information provided.", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"\"\n\n\"DURATION\": []\n\n[This sentence does not provide any information about durations of events.]", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" \"\"\n\n\"DURATION\": []\n\n\"This statement does not provide any information about the duration of an event or treatment.\"", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" No duration information provided.", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" No duration information provided.", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"DURATION\": []", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"DURATION\": []\n\n[11] refers to a research article, and it does not provide specific information about durations in the given context.", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" These are the following entities mentioned as herbs or extracts:\n\n* celery\n* echinacea\n* ginkgo\n* ginseng\n* hydroxycut\n* kava\n* kratom\n* moringa\n* piperine\n* rhodiola\n* St. John\u2019s wort\n* terminalia/commiphora ayurvedic mixture\n* valerian\n\nNo duration information was provided in the text.", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" No specific duration mentioned in the text.", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" No specific durations mentioned in this text.", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" \"DURATION\": [\"as shown by review and meta-analysis of published data\"]\n\nThe use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].\n\nNote: The duration of the studies is not explicitly stated in the text.", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" \"DURATION\": []", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"DURATION\": [\"in these human studies\"]\n\nThe exact durations of the studies mentioned in [27, 88] are not specified in the provided text.", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"DURATION\": [\"Chronic use\"]", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" {}\n\"ENTITY\": [\"kavalactones\"],\n\"DURATION\": []\n}\n\n\"The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes\"\n\nThis statement does not provide any information about the duration of events or processes. It only states that the pharmacological activities of kava are attributed to kavalactones, which are concentrated in the rhizomes. Therefore, no \"DURATION\" field is needed for this statement.", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" No specific duration mentioned in the text.", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" \"DURATION\": [\"\"]\n\nThis sentence does not provide any information about the duration of the study or treatment.", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"DURATION\": []", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" No duration information provided.", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" \"DURATION\": [\"in a 2-way, open-label crossover study\"]\n\nThis study did not provide information on the duration of the interaction between SJW and CYP3A4.", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" There is no specific duration mentioned in this statement.", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" No specific duration mentioned in the text.", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" {}\n\n\"DURATION\": []\n\nThis statement does not provide any information about durations of events. It only states that CYP3A4 and P-gp are richly expressed in human small intestinal enterocytes.", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" \"DURATION\": []", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" No specific durations mentioned in the text.\n\n\"DURATION\": []", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" {}\n\"DURATION\": []\n\nThis sentence does not provide any specific duration information. It only mentions that Sirolimus displays a synergistic action and has a distinctive mechanism of action from calcineurin inhibitors, which are used in kidney transplantation.", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" \"\"\n\n\"DURATION\": []\n\nThis statement does not provide any specific duration information. It is a general statement about drugs with a narrow therapeutic window.", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" \"DURATION\": [\"until April 2016\"]", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {}\n\n\"DURATION\": []\n\n(No duration information was provided in the text.)", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" No specific duration mentioned in the text.", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {}\n\n\"DURATION\": []\n\nThis information does not provide any information about durations of events.", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" No duration information provided.", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" \"\"DURATION\": []\"\"\"\n\nThis statement does not provide any specific duration information. It is a general recommendation for monitoring immunosuppressive drugs.", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" There is no mention of a specific duration related to Parsley (Petroselinum crispum) in the text.", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" \"DURATION\": []", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" There is no specific duration mentioned for the use of parsley in the context provided.\n\n\"DURATION\": []", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {}\n\n\"DURATION\": []\n\n(No duration information was provided in the text.)", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" No duration information provided.", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" \"DURATION\": []", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" {}\n\n\"DURATION\": []\n\n\"Sample size\": [\"n = 6\"]\n\n\"Data representation\": [\"mean \u00b1 S. D.\"]", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" \"DURATION\": [\"\"]\n\nThis passage does not provide any information about durations of events. It only mentions the analysis of AUC (Area Under the Curve) data and the possible herb-drug interaction between Epimedium sagittatum extract and sildenafil.", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" I'm unable to determine the duration from the given information. The abbreviation \"et al.\" stands for \"and others,\" indicating that multiple authors are credited for the work. It does not provide any information about the duration of an experiment or treatment.", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" \"DURATION\": [\"might have been too short\"]\n\nThis statement does not provide a specific duration for the pretreatment period, so it is left empty.", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" No duration information provided.", {}]], [841, "Maxim extract are available from the authors.", [" No information provided for \"DURATION\" in this text.", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"DURATION\": [\"\"]\n\nThis sentence does not provide any information about the duration of events or entities. It only mentions a review article as a source of information.", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" Regarding the duration, no specific information was provided in the given text.", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" \"DURATION\": [\"often over years\"]", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" No specific duration information provided in this sentence.", {}]], [846, "They found a prevalence of 56.6%.", [" \"DURATION\": [] # No duration information provided in the text.", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" \"DURATION\": [\"were conducted outside of the geographical area of this review\"]\n\nIn this context, it is unclear what the duration is for the surveys that did not ask for the species used or were conducted outside of the geographical area of the review.", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" No specific durations were mentioned in the text.\n\n\"Thus, two studies from Canada and the USA were screened to find plants that patients might use.\"", {}]], [849, "A Spanish study reports Aloe vera [37].", [" {\"DURATION\": []}", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" \"DURATION\": []", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" \"DURATION\": [\"short-term\"]", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"DURATION\": [\"every 2\u20133 days\"]", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" \"DURATION\": []", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" No specific duration mentioned in the text.\n\n\"DURATION\": []", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"DURATION\": []", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" {\"DURATION\": []}\n\n[154] refers to a European pharmacopoeia monograph, which does not provide information about the duration of any specific process or treatment.", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" {\"DURATION\": []}\n\n[154]: This information does not provide any duration information. It is just stating a limit for the ginkgolic acid content in the refined quantified dry extract.", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"DURATION\": [\"\"]\n\nThis information does not provide any specific duration information related to the study or experiment. It only mentions two references where cases of severe bleeding events associated with ginkgo have been reported.", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" \"DURATION\": [\"\"]\n\n(In vitro experiments do not have a specific duration mentioned in the text.)", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" It is important to note that the term \"ginseng\" can refer to various drugs derived from different plant species, such as Panax ginseng, American ginseng, or Asian ginseng. The specific duration of treatment with each type of ginseng may vary depending on the study or application.", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" I'm unable to extract any duration information from the given text as it only mentions the authors' name, Seong et al.", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"DURATION\": [\"despite the widespread use\"]\n\nIn this context, \"widespread use\" refers to the frequent consumption of tea, but no specific duration is mentioned in the text.", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"DURATION\": []", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" \"DURATION\": [\"after 3 weeks\"]", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"DURATION\": []", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" {\"DURATION\": [\"in vitro\"]}", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" \"DURATION\": [\"in humans\"]", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" \"DURATION\": [\"weekly\"]", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" \"\"DURATION\"\": []", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" No specific duration mentioned in the text.", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"DURATION\": []", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" I understand that there is a possibility for errors or misassignments when identifying entities in scientific texts, especially regarding species. It's essential to double-check the context and ensure accuracy when parsing the information.", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" No entities or durations found in this statement.", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" No duration information provided.", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" \"DURATION\": []", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"DURATION\": []", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about durations of events.", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"DURATION\": [\"for almost two millennia\"]", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" \"\"DURATION\": [\"\"]\n\nThis sentence does not provide any specific duration information.", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" \"DURATION\": []", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" \"\"DURATION\": [\"\"]}\n\nThis sentence does not provide any specific duration information. It only suggests that the findings from studies suggest an additive effect of Lycium when used in combination with conventional antidiabetics.", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" {}", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" \"DURATION\": []", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" No specific durations mentioned in this text.", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" This statement does not provide any information related to durations of events.", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"DURATION\": []", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" {\"DURATION\": []}\n\nThis information does not provide any durations of events.", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"DURATION\": [\"in several studies\"]", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" \"DURATION\": []", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" \"\"DURATION\"\": []", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" \"\"DURATION\"\": [\"\"]\n\nThis sentence does not provide any information about the duration of an event. It only mentions the type of column used for urine samples.", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" \"DURATION\": [\"\"]\n\nThis information does not provide any duration information related to events or treatments. It only mentions the statistical analysis method used and the significant P value.", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" {\"DURATION\": []}\n\nThis sentence does not provide any information about the duration of events or processes. It only mentions an in vitro study and the inhibition of DOR formation by Asafetida resin alcoholic extract in a concentration-dependent manner.", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" {\"DURATION\": []}\n\n\"The activation was highest at 25 \u03bcg/ml concentration.\" does not provide information about the duration of an event.", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" {}\n\n\"Subject\": [\"healthy human volunteers\"]\n\n\"DURATION\": []\n\n(Note: In this case, no specific duration information was provided in the text.)", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {}\n\n\"DURATION\": []\n\n(No specific duration information was provided in the text.)", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {}\n\n\"DURATION\": []\n\nThis conclusion statement does not provide any information about the duration of events or treatments in the study.", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" \"DURATION\": [\"causing dose reductions\", \"poor adherence\"]\n\nExplanation: The text mentions that abemaciclib-related diarrhea may lead to dose reductions and poor adherence, but it does not explicitly state the duration of these events. Therefore, the best information that can be extracted is the duration of the conditions that may lead to these events.", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" No specific durations were mentioned in this text.", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"DURATION\": [\"List of durations of events found in text\"]}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.\nRats were randomly divided into three groups, i.e., control (n = 6, vehicle treatment), single (n = 6, 1.5 g/kg), and multiple RGE treatments (n = 6, 1.5 g/kg for 7 days). [/INST]{\"DURATION\": [\"for 7 days\"]}</s> [INST] Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure. [/INST]{\"DURATION\": [\"after four days\"]}</s> [INST] Animal model experiments, surveys, and small pilot studies show potential benefits in IBD treatment over short periods (8 weeks), while longer use (6 months) is associated with a higher rate of surgery (reviewed in [123]). [/INST]{\"DURATION\": [\"8 weeks\", \"6 months\"]}</s> [INST] Importantly, rats in the multiple RGE group received RGE suspension (1.5 g/kg/3 mL/day) for 7 days via oral gavage, while rats in the single RGE treatment group received water (3 mL/kg) for 6 days via oral gavage and RGE suspension (1.5 g/kg/3 mL) via oral gavage on the day 7. [/INST]{\"DURATION\": [\"for 7 days\", \"for 6 days\"]}</s> [INST] In addition, the results of our study showed that supplementation of SC extract for 12 weeks in humans improved muscle strength (mean 7.7% for QMS). [/INST]{\"DURATION\": [\"for 12 weeks\"]}</s> [INST] TEXT HERE [/INST]"}